2 results
Approved WMORecruiting
Objectives Primary end point:- to define the MTD of IL-2, subcutaneously given once a day, 5 days per week, for 6 weeks, in combination with a fixed dose of sorafenib in patients with metastatic RCC, clear cell subtype. Secondary end points:- the…
Approved WMOPending
Uspio enhanced MRI (MRL) potentially has the ability to show all lymph nodes and hence provide information on metastasis in all nodes, this is in contrast with SLNB which only provides information on 1 (or a few) lymph node(s). With MRL metastases…